Interactions of buprenorphine and dipotassium clorazepate on anxiety and memory functions in the mouse

Drug and Alcohol Dependence

Volumn 85, Issue 2, 2006, Pages 103-113

  Lelong Boulouard, Véronique ^a,b   Quentin, Thomas ^c   Moreaux, Fabien ^a   Debruyne, Danièle ^b,c   Boulouard, Michel ^a   Coquerel, Antoine ^a,b  

^a UNIVERSITÉ DE CAEN   (France)

^b CHU CÔTE DE NACRE   (France)

^c GIP CYCERON   (France)

Author keywords

Benzodiazepine; Black and white box test; Partial mu receptor agonist; Passive avoidance test; Spontaneous locomotor activity; Y maze test

Indexed keywords

BUPRENORPHINE; CLORAZEPATE DIPOTASSIUM;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; HYPERACTIVITY; LOCOMOTION; LONG TERM MEMORY; MALE; MAZE TEST; MEMORY; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; REINFORCEMENT; SEDATION;

ANIMALS; ANTI-ANXIETY AGENTS; AROUSAL; AVOIDANCE LEARNING; BUPRENORPHINE; CLORAZEPATE DIPOTASSIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEAR; MALE; MAZE LEARNING; MEMORY, SHORT-TERM; MENTAL RECALL; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; NARCOTICS; RECEPTORS, OPIOID, MU; REINFORCEMENT (PSYCHOLOGY); RETENTION (PSYCHOLOGY);

EID: 33749126079     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2006.03.017     Document Type: Article

References (45)

1. Ageel A.M., Chin L., Trafton C.L., Jones B.C., and Picchioni A.L. Acute effects of morphine and chlorpromazine on the acquisition of shuttle box conditioned avoidance response. Psychopharmacologia 46 (1976) 311-315
2. Amano K., Takamatsu J., Ogata A., Katsuragi S., Miyazaki C., Deshimaru M., Sumiyoshi S., and Miyakawa T. Effect of dipotassium clorazepate on amygdaloid-kindling and comparison between amygdaloid- and hippocampal-kindled seizures in rats. Eur. J. Pharmacol. 385 (1999) 111-117
3. Boissier J.R., and Simon P. Action of caffeine on spontaneous activity in the mouse. Arch. Int. Pharmacodyn. Ther. 158 (1965) 212-221
4. Celerier A., Pierard C., and Beracochea D. BetaCCM enhances retrieval of serial contextual but not of serial spatial memory in mice. Behav. Pharmacol. 15 (2004) 123-131
5. Cleary J., Ho B., Nader M., and Thompson T. Effects of buprenorphine, methadone and naloxone on acquisition of behavioural chains. J. Pharmacol. Exp. Ther. 247 (1988) 569-575
6. Costall B., Jones B.J., Kelly M.E., Naylor R.J., and Tomkins D.M. Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol. Biochem. Behav. 32 (1989) 777-785
7. Cowan A. Buprenorphine: new pharmacological aspects. Int. J. Clin. Pract. Suppl. 133 (2003) 3-8
8. Debruyne D., Quentin T., Poisnel G., Lelong-Boulouard V., Barre L., and Coquerel A. Acute and chronic administration of clorazepate modifies the cell surface regulation of mu opioid receptors induced by buprenorphine in specific regions of the rat brain. Brain Res. 1052 (2005) 222-231
9. Drake C.T., and Milner T.A. Mu opioid receptors are in somatodendritic and axonal compartments of GABAergic neurons in rat hippocampal formation. Brain Res. 849 (1999) 203-215
10. Frey H.H., and Scherkl R. Clorazepate, correlation between metabolism and anticonvulsant activity. Eur. J. Pharmacol. 158 (1988) 213-216
11. Gades N.M., Danneman P.J., Wixson S.K., and Tolley E.A. The magnitude and duration of the analgesic effect of morphine, butorphanol, and buprenorphine in rats and mice. Contemp. Top. Lab. Anim. Sci. 39 (2000) 8-13
12. Gowing L., Ali R., and White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst. Rev. 2 (2002) CD002025
13. Griebel G., Sanger D.J., and Perrault G. Further evidence for differences between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands in murine models of "state" and "trait" anxiety. Neuropharmacology 35 (1996) 1081-1091
14. Hiramatsu M., Hoshino T., Kameyama T., and Nabeshima T. Involvement of kappa-opioid and sigma receptors in short-term memory in mice. Eur. J. Pharmacol. 453 (2002) 91-98
15. Hooper N., Fraser C., and Stone T.W. Effects of purine analogues on spontaneous alternation in mice. Psychopharmacology 123 (1996) 250-257
16. Huang P., Kehner G.B., Cowan A., and Liu-Chen L.Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharm. Exp. Therap. 297 (2001) 688-695
17. Jarvik M.E., and Kopp R. An improved one-trial passive avoidance learning situation. Psychol. Rep. 21 (1967) 221-224
18. Kuribara H., Asashi T., and Tadokoro S. Enhancement of the ambulation-increasing effect of opioid analgesics by ethanol in mice. Jpn. J. Pharmacol. 56 (1991) 457-463
19. Mansour A., Fox C.A., Akil H., and Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18 (1995) 22-29
20. Marin S., Marco E., Biscaia M., Fernandez B., Rubio M., Guaza C., Schmidhammer H., and Viveros M.P. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol. Biochem. Behav. 74 (2003) 649-656
21. Megarbane B., Gueye P., and Baud F. Interactions between benzodiazepines and opioids. Ann. Med. Internet 154 (2003) 2S64-2S72
22. 2C receptor blockade. Psychopharmacology 177 (2005) 448-458
23. Moller H.J. Effectiveness and safety of benzodiazepines. J. Clin. Psychopharmacol. 19 Suppl. 2 (1999) 2S-11S
24. Nielsen S., and Taylor D.A. The effect of buprenorphine and benzodiazepines on respiration in the rat. Drug Alcohol Depend. 79 (2005) 95-101
25. Ochs M.W., Tucker M.R., and White Jr. R.P. A comparison of amnesia in outpatients sedated with midazolam or diazepam alone or in combination with fentanyl during oral surgery. J. Am. Dent. Assoc. 113 (1986) 894-897
26. Ohtani M., Kotaki H., Nishitateno K., Sawada Y., and Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J. Pharmacol. Exp. Ther. 28 (1997) 428-433
27. Privette T.H., and Terrian D.M. Kappa opioid agonists produce anxiolytic-like behaviour on the elevated plus-maze. Psychopharmacology 118 (1995) 444-450
28. Quentin T., Debruyne D., Lelong-Boulouard V., Poisnel G., Barre L., and Coquerel A. Clorazepate affects cell surface regulation of delta and kappa opioid receptors, thereby altering buprenorphine-induced adaptation in the rat brain. Brain Res. 1063 (2005) 84-95
29. Rattan A.K., and Sribanditmongkol P. Effect of morphine-induced catalepsy, lethality, and analgesia by a benzodiazepine receptor agonist midazolam in the rat. Pharmacol. Biochem. Behav. 48 (1994) 357-361
30. Reynaud M., Petit G., Potard D., and Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 93 (1998) 1385-1392
31. Romero D.V., Partilla J.S., Zheng Q.X., Heyliger S.O., Ni Q., Rice K.C., Lai J., and Rothman R.B. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay. Synapse 34 (1999) 83-94
32. Saha N., Datta H., and Sharma P.L. Effects of morphine, buprenorphine, pentazocine and nalorphine on acquisition and extinction of active avoidance responses in rats. Ind. J. Physiol. Pharmacol. 34 (1990) 179-182
33. Sasaki K., Fan L.W., Tien L.T., Ma T., Loh H.H., and Ho I.K. The interaction of morphine and gamma-aminobutyric acid (GABA)ergic systems in anxiolytic behaviour: using mu-opioid receptor knockout mice. Brain Res. Bull. 57 (2002) 689-694
34. Schmaltz K., and Katz R.J. Y-maze behaviour in the mouse after morphine or an enkephalin analog. Psychopharmacology 74 (1981) 99-100
35. Shannon H.E. Stimulation of avoidance behaviour by buprenorphine in rats. Psychopharmacology 80 (1983) 19-23
36. Shephard R.A. Neurotransmitters, anxiety and benzodiazepines: a behavioural review. Neurosci. Biobehav. Rev. 10 (1986) 449-461
37. Shiigi Y., Takahashi M., and Kaneto H. Facilitation of memory retrieval by pretest morphine mediated by mu but not delta and kappa opioid receptors. Psychopharmacology 102 (1990) 329-332
38. Thiebot M.H. Some evidence for amnestic-like effects of benzodiazepines in animals. Neurosci. Biobehav. Rev. 9 (1985) 95-100
39. Thirion X., Lapierre V., Micallef J., Ronfle E., Masut A., Pradel V., Coudert C., Mabriez J.C., and Sanmarco J.L. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend. 65 (2002) 197-204
40. Thompson R.F., and Kim J.J. Memory systems in the brain and localization of a memory. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 13438-13444
41. Toll L., Berzetei-Gurske I.P., Polgar W.E., Brandt S.R., Adapa I.D., Rodriguez L., Schwartz R.W., Haggart D., O'Brien A., and White A. Standard binding and functional assay related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res. Monogr. 178 (1998) 440-466
42. Tzschentke T.M. Behavioural pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology 161 (2002) 1-16
43. Ukai M., Watanabe Y., and Kameyama T. Endomorphins 1 and 2, endogenous mu-opioid receptor agonists, impair passive avoidance learning in mice. Eur. J. Pharmacol. 421 (2001) 115-119
44. Wagner J.J., Etemad L.R., and Thompson A.M. Opioid-mediated facilitation of long-term depression in rat hippocampus. J. Pharmacol. Exp. Ther. 296 (2001) 776-781
45. Walker B.M., and Ettenberg A. Benzodiazepine modulation of opiate reward. Exp. Clin. Psychopharmacol. 9 (2001) 191-197